Market News

U.S. FDA Removes Clinical Hold For BEAM Drug Candidate

Shares of Beam Therapeutics Inc. (NASDAQ: BEAM) were down in morning trading on Friday even as the biotechnology company announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold and cleared the Investigational New Drug (IND) application for BEAM-201.

BEAM-201 is the company’s drug candidate for the treatment of acute lymphoblastic leukemia.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More